论文部分内容阅读
目的:观察氯雷他定糖浆佐治小儿过敏性紫癜的临床疗效。方法:将确诊为小儿过敏性紫癜的患儿120例,随机分为治疗组和对照组各60例,两组均给予常规对症综合治疗,治疗组在常规治疗基础上给予口服氯雷他定糖浆,体重≤30 kg,每次5 mg,体重>30 kg,每次10 mg,每天1次,疗程10～14 d,观察两组患儿临床症状、体征改善情况及不良反应。结果:治疗组总有效率91.7%,对照组总有效率78.3%,两组比较差异有统计学意义(χ2=17.47,P<0.05);治疗组皮肤紫癜消退时间、关节肿痛消失时间、腹痛消失时间、血尿及蛋白尿消失时间及住院时间均短于对照组,两组比较差异有统计学意义(P<0.01);不良反应发生率两组比较差异有统计学意义(χ2=4.93,P<0.05)。结论:氯雷他定佐治小儿过敏性紫癜安全有效,能有效缩短治愈时间。
Objective: To observe the clinical efficacy of loratadine syrup in treating children with Henoch-Schonlein purpura. Methods: A total of 120 children with Henoch-Schonlein purpura were randomly divided into treatment group (60 cases) and control group (60 cases). Both groups were given general symptomatic and comprehensive treatment. The treatment group was given oral loratadine syrup , Weight ≤30 kg, 5 mg each time, body weight> 30 kg, each time 10 mg, once a day, the course of treatment was 10 ~ 14 days. The clinical symptoms, signs and symptoms and adverse reactions in both groups were observed. Results: The total effective rate was 91.7% in the treatment group and 78.3% in the control group. There was significant difference between the two groups (χ2 = 17.47, P <0.05). The skin purpura regression time, disappearance of joint swelling and pain, abdominal pain Disappear time, hematuria and proteinuria disappear time and hospitalization time are shorter than the control group, the difference between the two groups was statistically significant (P <0.01); Adverse reactions between the two groups was statistically significant difference (χ2 = 4.93, P <0.05). Conclusion: Loratadine adjuvant treatment of allergic purpura in children safe and effective, can effectively reduce the healing time.